| Filed On | Filing |
|---|---|
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 |
| 27 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio |
| 25 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
BROADEN2 enrollment completed nearly six months ahead of anticipated timelines |
| 24 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Kymera Therapeutics, Inc. (the “Company”) held its Annual Meeting of Shareholders on June 24, 2026 (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders considered and voted on the three proposals set forth below, eac... |
| 08 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition
KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively |
| 27 Mar 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Section 8 of Article VI of the Second Amended and Restated Bylaws of the Corporation (the “Bylaws”) is hereby amended and restated in its entirety as follows: |
| 26 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
Kymera Therapeutics, Inc. (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 |
| 13 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 |
| 10 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Kymera Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Je... |
| 08 Dec 2025 |
8-K: Regulation FD Disclosure
Exhibit 99.1 KT-621, Oral STAT6 Degrader, Phase 1b Results 1 |
| 08 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
Enrollment and dosing completed in KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data to be reported in December 2025 |
| 03 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Watertown, Mass. (September 3, 2025) – Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the a... |
| 11 Aug 2025 |
8-K: Results of Operations and Financial Condition
Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile |
| 27 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Kymera Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Je... |
| 27 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Kymera Therapeutics, Inc. (the “Company”) held its Annual Meeting of Shareholders on June 25, 2025 (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders considered and voted on the three proposals set forth below, eac... |
| 25 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 |
Loading...